CoChat

Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Objective: Campylobacter jejuni produces a genotoxin, cytolethal distending toxin (CDT), which has DNAse activity and causes DNA double-strand breaks. Although C. jejuni infection has been shown to promote intestinal inflammation, the impact of this bacterium on carcinogenesis has never been examined. Design: Germ-free (GF) Apc Min/+ mice, fed with 1% dextran sulfate sodium, were used to test tumorigenesis potential of CDT-producing C. jejuni . Cells and enteroids were exposed to bacterial lysates to determine DNA damage capacity via γH2AX immunofluorescence, comet assay and cell cycle assay. To examine the interplay of CDT-producing C. jejuni , gut microbiome and host in tumorigenesis, colonic RNA-sequencing and faecal 16S rDNA sequencing were performed. Rapamycin was administrated to investigate the prevention of CDT-producing C. jejuni -induced tumorigenesis. Results: GF Apc Min/+ mice colonised with human clinical isolate C. jejuni 81–176 developed significantly more and larger tumours when compared with uninfected mice. C. jejuni with a mutated cdtB subunit, mut cdtB , attenuated C. jejuni -induced tumorigenesis in vivo and decreased DNA damage response in cells and enteroids. C. jejuni infection induced expression of hundreds of colonic genes, with 22 genes dependent on the presence of c dtB. The C. jejuni -infected group had a significantly different microbial gene expression profile compared with the mut cdtB group as shown by metatranscriptomic data, and different microbial communities as measured by 16S rDNA sequencing. Finally, rapamycin could diminish the tumorigenic capability of C. jejuni . Conclusion: Human clinical isolate C. jejuni 81–176 promotes colorectal cancer and induces changes in microbial composition and transcriptomic responses, a process dependent on CDT production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-317200

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Human clinical isolate C. jejuni 81–176 promotes colorectal tumorigenesis and tumour growth in mice. (A) Schematic diagram showing the experimental design for colorectal cancer (CRC). A cohort of GF ApcMin/+ mice (n=5–7) were transferred to a specific-pathogen-free (SPF) environment and immediately gavaged with a single dose (105 CFU) of C. jejuni (or PBS in control group). After 14 days, the mice were exposed to 1% dextran sulfate sodium (DSS) for 10 days and euthanised 3 weeks post-DSS. (B) Representative colonoscopy, (C) macroscopic morphologies and (D) H&E-stained colon sections of mice in control and C. jejuni groups. (E) Macroscopic colon tumour counts from mice in control (n=5) and C. jejuni (n=7) groups. (F) Histological inflammation score and (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) from mice in control and C. jejuni groups. Data, mean±SEM. Mann-Whitney U test. *p<0.05; GF, germ-free; NS, not significant.
Figure 1 Human clinical isolate C. jejuni 81–176 promotes colorectal tumorigenesis and tumour growth in mice. (A) Schematic diagram showing the experimental design for colorectal cancer (CRC). A cohort of GF ApcMin/+ mice (n=5–7) were transferred to a specific-pathogen-free (SPF) environment and immediately gavaged with a single dose (105 CFU) of C. jejuni (or PBS in control group). After 14 days, the mice were exposed to 1% dextran sulfate sodium (DSS) for 10 days and euthanised 3 weeks post-DSS. (B) Representative colonoscopy, (C) macroscopic morphologies and (D) H&E-stained colon sections of mice in control and C. jejuni groups. (E) Macroscopic colon tumour counts from mice in control (n=5) and C. jejuni (n=7) groups. (F) Histological inflammation score and (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) from mice in control and C. jejuni groups. Data, mean±SEM. Mann-Whitney U test. *p<0.05; GF, germ-free; NS, not significant.CC BY-NC · PubMed Central
Figure 2 C. jejuni CdtB subunit is critical for DNA damage in vitro. IEC-6, HT-29 and mouse enteroids were exposed to bacterial lysates from C. jejuni-wild type (WT) or mutcdtB. Cells were incubated with lysates (5 µg/mL) or PBS for 24 hours for γH2AX staining and comet assay, or 48 hours for cell cycle analysis. Enteroids were incubated with lysates (50 µg/mL) for 12 hours. (A) Representative images of γH2AX immunofluorescence staining, (B) γH2AX flow cytometry histograms, (C) comet assay and (D) cell cycle histograms showing IEC-6 cells (left panel) and HT-29 cells (right panel) treated with PBS (control), or lysates from C. jejuni or mutcdtB. (E) Representative images of γH2AX immunofluorescence staining in enteroids incubated with PBS (control) or bacterial lysates. At least four independent experiments were performed. Data, mean±SEM χ2 test. ****p<0.0001; NS, not significant.
Figure 2 C. jejuni CdtB subunit is critical for DNA damage in vitro. IEC-6, HT-29 and mouse enteroids were exposed to bacterial lysates from C. jejuni-wild type (WT) or mutcdtB. Cells were incubated with lysates (5 µg/mL) or PBS for 24 hours for γH2AX staining and comet assay, or 48 hours for cell cycle analysis. Enteroids were incubated with lysates (50 µg/mL) for 12 hours. (A) Representative images of γH2AX immunofluorescence staining, (B) γH2AX flow cytometry histograms, (C) comet assay and (D) cell cycle histograms showing IEC-6 cells (left panel) and HT-29 cells (right panel) treated with PBS (control), or lysates from C. jejuni or mutcdtB. (E) Representative images of γH2AX immunofluorescence staining in enteroids incubated with PBS (control) or bacterial lysates. At least four independent experiments were performed. Data, mean±SEM χ2 test. ****p<0.0001; NS, not significant.CC BY-NC · PubMed Central
Figure 3 C. jejuni-induced tumorigenesis in ApcMin/+/dextran sulfate sodium (DSS) mice and requires functional cdtB. (A) Schematic diagram showing the experimental design. A cohort of germ-free (GF) ApcMin/+ mice (n=7–9) was transferred to a specific-pathogen-free (SPF) environment and immediately gavaged with a single dose (105 CFU) of C. jejuni (wild type (WT) or mutcdtB). After 14 days, the mice were exposed to 1% DSS for 10 days and euthanised 3 weeks post-DSS. (B) Representative colonoscopy images, (C) macroscopic morphologies and (D) H&E-stained colon of mice infected with C. jejuni-WT or mutcdtB. (E) Macroscopic tumour counts from mice in C. jejuni-WT group (n=7) and mutcdtB group (n=9). (F) Histological inflammation score and (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) from mice in C. jejuni-WT group and mutcdtB group. (H) CFU counts of C. jejuni in the stool of mice colonised with C. jejuni-WT and mutcdtB at different time points. (I) Presence of C. jejuni (red dot) in colonic sections from infected mice at the end point of experiment, detect by fluorescence in situ hybridisation (FISH) assay. Data, mean±SEM Mann-Whitney U test. ***p=0.0002; NS, not significant.
Figure 3 C. jejuni-induced tumorigenesis in ApcMin/+/dextran sulfate sodium (DSS) mice and requires functional cdtB. (A) Schematic diagram showing the experimental design. A cohort of germ-free (GF) ApcMin/+ mice (n=7–9) was transferred to a specific-pathogen-free (SPF) environment and immediately gavaged with a single dose (105 CFU) of C. jejuni (wild type (WT) or mutcdtB). After 14 days, the mice were exposed to 1% DSS for 10 days and euthanised 3 weeks post-DSS. (B) Representative colonoscopy images, (C) macroscopic morphologies and (D) H&E-stained colon of mice infected with C. jejuni-WT or mutcdtB. (E) Macroscopic tumour counts from mice in C. jejuni-WT group (n=7) and mutcdtB group (n=9). (F) Histological inflammation score and (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) from mice in C. jejuni-WT group and mutcdtB group. (H) CFU counts of C. jejuni in the stool of mice colonised with C. jejuni-WT and mutcdtB at different time points. (I) Presence of C. jejuni (red dot) in colonic sections from infected mice at the end point of experiment, detect by fluorescence in situ hybridisation (FISH) assay. Data, mean±SEM Mann-Whitney U test. ***p=0.0002; NS, not significant.CC BY-NC · PubMed Central
Figure 4 Cytolethal distending toxin (CDT)-producing C. jejuni impacts mouse and bacterial transcriptomes. RNA from distal colon tissues of mice infected with C. jejuni-wild type (WT) (n=3), mutcdtB (n=3) and controls (n=3) were subject to RNA-seq. Principal component analysis (PCA) comparing mouse transcriptomes between (A) C. jejuni group and control group, (B) mutcdtB group and control group and (C) C. jejuni group and mutcdtB group. PCA comparing bacterial transcriptomes between (D) C. jejuni group and control group, (E) mutcdtB group and control group and (F) C. jejuni group and mutcdtB group.
Figure 4 Cytolethal distending toxin (CDT)-producing C. jejuni impacts mouse and bacterial transcriptomes. RNA from distal colon tissues of mice infected with C. jejuni-wild type (WT) (n=3), mutcdtB (n=3) and controls (n=3) were subject to RNA-seq. Principal component analysis (PCA) comparing mouse transcriptomes between (A) C. jejuni group and control group, (B) mutcdtB group and control group and (C) C. jejuni group and mutcdtB group. PCA comparing bacterial transcriptomes between (D) C. jejuni group and control group, (E) mutcdtB group and control group and (F) C. jejuni group and mutcdtB group.CC BY-NC · PubMed Central
Figure 5 Cytolethal distending toxin (CDT)-producing C. jejuni alters microbial compositions. DNA from stool samples collected at 14 days and 45 days following infection with C. jejuni-wild type (WT) (n=7), mutcdtB (n=7) and uninfected controls (n=5) were subjected to 16S rDNA sequencing. Shannon Diversity Index comparing C. jejuni, mutcdtB and controls at (A) 14 days time point (control vs C. jejuni p value=0.15, control vs mutcdtB p value=2.20E-05 and mutcdtB vs C. jejuni p value=2.72E-05) and (B) 45 days time point (control vs C. jejuni p value=0.65, control vs mutcdtB p value=2.10E-07 and mutcdtB vs C. jejuni p value=5.14E-09). Principal coordinates analysis (PCoA) comparing microbial compositions in faecal samples at 45 days time point between: (C) C. jejuni group and control group, (D) mutcdtB group and control group, and (E) C. jejuni group and mutcdtB group. (F) Heat map representation of families significantly different (FDR-adjusted p value<0.05) between mice infected with C. jejuni, mutcdtB and controls at (F) 14 days time point and (G) 45 days time point. ****p<0.0001; NS, not significant.
Figure 5 Cytolethal distending toxin (CDT)-producing C. jejuni alters microbial compositions. DNA from stool samples collected at 14 days and 45 days following infection with C. jejuni-wild type (WT) (n=7), mutcdtB (n=7) and uninfected controls (n=5) were subjected to 16S rDNA sequencing. Shannon Diversity Index comparing C. jejuni, mutcdtB and controls at (A) 14 days time point (control vs C. jejuni p value=0.15, control vs mutcdtB p value=2.20E-05 and mutcdtB vs C. jejuni p value=2.72E-05) and (B) 45 days time point (control vs C. jejuni p value=0.65, control vs mutcdtB p value=2.10E-07 and mutcdtB vs C. jejuni p value=5.14E-09). Principal coordinates analysis (PCoA) comparing microbial compositions in faecal samples at 45 days time point between: (C) C. jejuni group and control group, (D) mutcdtB group and control group, and (E) C. jejuni group and mutcdtB group. (F) Heat map representation of families significantly different (FDR-adjusted p value<0.05) between mice infected with C. jejuni, mutcdtB and controls at (F) 14 days time point and (G) 45 days time point. ****p<0.0001; NS, not significant.CC BY-NC · PubMed Central
Figure 6 Rapamycin alleviates C. jejuni-promoted colorectal tumorigenesis and tumour growth in ApcMin/+/dextran sulfate sodium (DSS) mice. (A) Schematic diagram showing the experimental design. Cohorts of germ-free (GF) ApcMin/+ mice (n=7–8) orally infected with C. jejuni (105 CFU) were intraperitoneally injected with rapamycin (1.5 mg/kg body weight, daily) for 14 days, and subsequently exposed to 1% DSS for 10 days. Three weeks post-DSS, the mice were euthanised. (B) Representative colonoscopy images, (C) macroscopic morphologies and (D) H&E staining sections from colons of mice in control group (n=7) and rapamycin group (n=8). (E) Macroscopic tumour counts of mice in control group and rapamycin group. Two independent experiments were performed. (F) Histological inflammation score, (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) and (H) p-S6 (S235/236) IHC from mice in control group and rapamycin group. (I) CFU counts of C. jejuni in the stool from mice in control group and rapamycin group at different time points. Data, mean±SEM Mann-Whitney U test. ***p=0.0003; NS, not significant.
Figure 6 Rapamycin alleviates C. jejuni-promoted colorectal tumorigenesis and tumour growth in ApcMin/+/dextran sulfate sodium (DSS) mice. (A) Schematic diagram showing the experimental design. Cohorts of germ-free (GF) ApcMin/+ mice (n=7–8) orally infected with C. jejuni (105 CFU) were intraperitoneally injected with rapamycin (1.5 mg/kg body weight, daily) for 14 days, and subsequently exposed to 1% DSS for 10 days. Three weeks post-DSS, the mice were euthanised. (B) Representative colonoscopy images, (C) macroscopic morphologies and (D) H&E staining sections from colons of mice in control group (n=7) and rapamycin group (n=8). (E) Macroscopic tumour counts of mice in control group and rapamycin group. Two independent experiments were performed. (F) Histological inflammation score, (G) proliferating cell nuclear antigen (PCNA) and β-catenin immunohistochemistry (IHC) and (H) p-S6 (S235/236) IHC from mice in control group and rapamycin group. (I) CFU counts of C. jejuni in the stool from mice in control group and rapamycin group at different time points. Data, mean±SEM Mann-Whitney U test. ***p=0.0003; NS, not significant.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 409

Metadata

Authors
He, Z., Gharaibeh, R. Z., Newsome, R. C., Pope, J. L., Dougherty, M. W., Tomkovich, S., Pons, B., Mirey, G., Vignard, J., Hendrixson, D. R., & Jobin, C.
Affiliations
  • Sun Yat-sen University (CN)
  • University of Florida (US)
  • University of Florida Health (US)
  • Toxalim (Research Center in Food Toxicology), Université de Toulouse, INRA, ENVT, INP- Purpan, UPS, Toulouse, France
  • Université Toulouse III - Paul Sabatier (FR)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
Jobin, Christian
Venue
Gut
Publisher
BMJ
Published
2018-10-30
Volume
68
Issue
2
Pages
289-300
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2899303925
Cited by
409
References
42
Citations by year
2026: 46 · 2025: 56 · 2024: 59 · 2023: 64 · 2022: 58 · 2021: 57 · 2020: 48 · 2019: 21
FWCI
29.57
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Gut (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
Keywords
Campylobacter jejuni, cytolethal distending toxin, colorectal carcinogenesis, colorectal cancer, DNA damage response, ApcMin/+ mice, germ-free mice, gut microbiota, cdtB, dextran sulfate, enteroids, metatranscriptomics, rapamycin, bacterial genotoxins, DNA double-strand breaks
MeSH terms
Gastrointestinal Microbiome, Animals, Bacterial Toxins, DNA Damage, DNA, Neoplasm, Feces, Humans, RNA, Neoplasm, Colorectal Neoplasms, Gene Expression, Campylobacter jejuni, Sirolimus, Mice, Transcriptome, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. https://app.cochat.ai/papers/10.1136/gutjnl-2018-317200
The paper
He, Z., Gharaibeh, R. Z., Newsome, R. C., Pope, J. L., Dougherty, M. W., Tomkovich, S., Pons, B., Mirey, G., Vignard, J., Hendrixson, D. R., & Jobin, C. (2019). Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut. https://doi.org/10.1136/gutjnl-2018-317200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.